-
- We work continuously to improve our understanding of the way in which our pharmaceuticals interact with the environment.
- Our environmental scientists are at the forefront of PiE research.
AstraZeneca understands, and takes seriously, the concerns over the detections of trace amounts of pharmaceutical residues in the environment. We are continually improving our understanding of the science and the way we responsibly manage our products.
The presence of trace levels of pharmaceuticals in the environment results largely from patient excretion and is an inevitable result of the way most current medicines work. Pharmaceuticals need to be stable enough to have a useful shelf life and oral dosage forms must be robust enough to pass through the stomach intact.
Internally and in cooperation with other companies, academics and regulators, we are pursuing a wide range of actions that help us understand and manage the way our products interact with the environment. We are committed to identifying any potential adverse affects on the environment and responsibly balancing these against the benefits that our medicines bring to patients lives.
Our environmental scientists, located mainly at our Environmental Laboratory in Brixham, UK, are dedicated to advancing PiE related research. In 2007 we opened a new, $26 million laboratory in Brixham to strengthen further our capabilities in this area.
We also design our manufacturing processes to minimise impact on the environment and encourage patients to follow government unused medicine disposal guidelines.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 06:25 GMT
Detailed share price